The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Open accessAbstract
Osteoprotegerin (OPG) is a secreted protein that inhibits osteoclast formation. In this study the physiological role of OPG is investigated by generating OPG-deficient mice. Adolescent and adult OPG-/- mice exhibit a decrease in total bone density characterized by severe trabecular and cortical bone porosity, marked thinning of the parietal bones of the skull, and a high incidence of fractures. These findings demonstrate that OPG is a critical regulator of postnatal bone mass. Unexpectedly, OPG-deficient mice also exhibit medial calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling pathway, or its ligand(s) may play a role in the long observed association between osteoporosis and vascular calcification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“overexpression of OPG produced osteopetrosis, while OPG-knockout mice had a phenotype of severe osteoporosis with a high incidence of fractures”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [46]
In the citing paper
“The essential physiological role of OPG in maintaining bone mass was shown by the severe osteopenic phenotype of OPG knockout mice (124 -126).These mice exhibit increased bone turnover, cortical porosity, and reductions in cortical and cancellous bone volume and density.These deleterious changes are accompanied by spontaneous fragility fractures in the first weeks of life (124).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [124]
In the citing paper
“OPG knockout animals developed medial calcification of the aorta and renal arteries, in association with elevated bone turnover (124).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationSpontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
Luo, G., Ducy, P. F., McKee, M. D., Pinero, G. J., Loyer, E. M., Behringer, R. R., & Karsenty, G. (1997) · Nature · doi:10.1038/386078a0 · Cited by 2,118
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P. M., Montgomery, C. A., Geske, R. S., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 1,997
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789
Manolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,670
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440
Bone morphogenetic protein expression in human atherosclerotic lesions.
Boström, K. I., Watson, K. E., Horn, S. E. V., Wortham, C., Herman, I. M., & Demer, L. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116391 · Cited by 1,020
OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION
Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934
Bone and haematopoietic defects in mice lacking c-fos
Wang, Z., Ovitt, C. E., Grigoriadis, A. E., Möhle-Steinlein, U., Rüther, U., & Wagner, E. F. (1992) · Nature · doi:10.1038/360741a0 · Cited by 932
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., & Boyce, B. F. (1996) · Nature Medicine · doi:10.1038/nm1096-1132 · Cited by 813 · cited 1×
“Some systemic and local factors that regulate development and interplay between osteoclasts and osteoblasts have been identified (Mundy 1993a,b; Erlebacher and Derynck 1996; Manolagas and Jilka 1995; Hughes et al. 1996; Pacifici 1996).”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–127 of 127
Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation
Souza, P. P. C., & Lerner, U. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01663 · Cited by 67
“To counteract RANKL action, a decoy receptor lacking a transmembrane domain, osteoprotegerin (OPG), competes with RANK for RANKL binding and blocks osteoclast differentiation and activation (32, 33).”
BackgroundOsteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66
Self-citationSkoumal, M., Kolarz, G., Haberhauer, G., Woloszczuk, W., Hawa, G., & Klingler, A. (2005) · Rheumatology International · doi:10.1007/s00296-004-0579-1 · Cited by 66
Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, S.-I., Kobayashi, N., Fujimoto, H., Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1601 · Cited by 64
Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62
Oh, E. S., Rhee, E.-J., Oh, K. W., Lee, W. Y., Baek, K. H., Yoon, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Choi, M. G., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.005 · Cited by 61
Osteoprotegerin Protects against Muscular Dystrophy
Dufresne, S. S., Dumont, N. A., Bouchard, P., Lavergne, É., Penninger, J. M., & Frenette, J. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.006 · Cited by 61
An integrated multi-omics analysis reveals osteokines involved in global regulation
Liang, W., Wei, T., Hu, L., Chen, M., Tong, L., Zhou, W., Duan, X., Zhao, X., Zhou, W., Jiang, Q., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.006 · Cited by 67
Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen
Bord, S., Frith, E., Ireland, D. C., Scott, M. A., Craig, J. I. O., & Compston, J. E. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05024.x · Cited by 56
Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
Nakamichi, Y., Udagawa, N., Kobayashi, Y., Nakamura, M., Yamamoto, Y., Yamashita, T., Mizoguchi, T., Sato, M., Mogi, M., Penninger, J. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.192 · Cited by 50
Pathogenesis of bone lesions in rheumatoid arthritis.
Goldring, S. R., & Gravallese, E. M. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0069-y · Cited by 44
Tschiderer, L., Willeit, J., Schett, G., Kiechl, S., & Willeit, P. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183910 · Cited by 45
Osteoprotegerin expression in dendritic cells increases with maturation and is NF‐κB‐dependent
Schoppet, M., Henser, S., Ruppert, V., Stübig, T., Al‐Fakhri, N., Maisch, B., & Hofbauer, L. C. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21129 · Cited by 45
Regulatory effects of osteoprotegerin on cellular and humoral immune responses.
Stolina, M., Guo, J., Faggioni, R., Brown, H., & Senaldi, G. (2003) · Clinical Immunology · doi:10.1016/j.clim.2003.09.001 · Cited by 44
Middleton-Hardie, C., Zhu, Q., Cundy, H., Lin, J.-M., Callon, K., Tong, P. C., Xu, J., Grey, A., Cornish, J., & Naot, D. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051104 · Cited by 41
Interactions of B-lymphocytes and bone cells in health and disease
Grčević, D., Sanjay, A., & Lorenzo, J. (2023) · Bone · doi:10.1016/j.bone.2021.116296 · Cited by 36
A toxicity profile of osteoprotegerin in the cynomolgus monkey.
Smith, B. B., Cosenza, M. E., Mancini, A., Dunstan, C., Gregson, R., Martin, S. W., Smith, S. Y., & Davis, H. (2003) · International Journal of Toxicology · doi:10.1177/109158180302200512 · Cited by 33
Self-citationMancini, L., Paul-Clark, M. J., Rosignoli, G., Hannon, R., Martin, J. E., Macintyre, I., & Perretti, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060830 · Cited by 32
Kanematsu, M., Yoshimura, K., Takaoki, M., & Sato, A. (2002) · Bone · doi:10.1016/s8756-3282(02)00680-4 · Cited by 31
Quinn, J. E., Brown, L. G., Zhang, J., Keller, E. T., Vessella, R. L., & Corey, E. (2005) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500815 · Cited by 29
Kahl, K. G., Rudolf, S., Dibbelt, L., Stoeckelhuber, B. M., Gehl, H.-B., Hohagen, F., & Schweiger, U. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1711-5 · Cited by 27
Age-related bone loss is associated with FGF21 but not IGFBP1 in healthy adults
Lee, S. Y., Fam, K. D., Chia, K. L., Yap, M. M. C., Goh, J., Yeo, K. P., Yap, E. P. H., Chotirmall, S. H., & Lim, C. L. (2020) · Experimental Physiology · doi:10.1113/ep088351 · Cited by 24
Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.
Bateman, T. A., Dunstan, C. R., Lacey, D. L., Ferguson, V. L., Ayers, R. A., & Simske, S. J. (2001) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(00)00057-7 · Cited by 22
Self-citationTramadol enhances PGF2α-stimulated osteoprotegerin synthesis in osteoblasts
Kim, W., Tanabe, K., Kuroyanagi, G., Matsushima-Nishiwaki, R., Fujita, K., Kawabata, T., Sakai, G., Tachi, J., Hioki, T., Nakashima, D., et al. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e04779 · Cited by 8
Bone Homeostasis: An Emerging Role for the Renin-Angiotensin System
Sernia, C., Huang, H., Nguyuen, K., Li, Y.-H., Hsu, S., Chen, M., Yu, N., & Forwood, M. (2007) · Frontiers in Research of the Renin-Angiotensin System on Human Disease · doi:10.1007/978-1-4020-6372-5_9 · Cited by 4
Hioki, T., Tokuda, H., Tanabe, K., Kim, W., Tachi, J., Yamaguchi, S., Matsushima-Nishiwaki, R., Kozawa, O., & Iida, H. (2021) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2021.102323 · Cited by 2
Metadata
- Authors
- Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., & Simonet, W. S.
- Affiliations
- Amgen (United States) (US)
- ORCID
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1998-05-01
- Volume
- 12
- Issue
- 9
- Pages
- 1260-1268
- ISSN
- 0890-9369 (ISSN-L)
- PMC
- PMC316769
- OpenAlex
- W2129651548
- Cited by
- 2,483
- References
- 42
- Citations by year
- 2026: 29 · 2025: 29 · 2024: 46 · 2023: 43 · 2022: 52 · 2021: 61 · 2020: 90 · 2019: 62 · 2018: 53 · 2017: 93 · 2016: 82 · 2015: 94 · 2014: 89 · 2013: 122 · 2012: 106
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
- Keywords
- osteoprotegerin, osteoporosis, arterial calcification, vascular calcification, osteoclastogenesis, bone mineral density, trabecular bone, cortical bone, bone porosity, fracture, renal artery calcification
- MeSH terms
- Animals, Arteries, Calcinosis, Disease Models, Animal, Female, Glycoproteins, Male, Osteoporosis, Vascular Diseases, Bone Density, In Situ Hybridization, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mice, Knockout, Gene Targeting, Mice, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
